Gene therapy for wet AMD: could this mean fewer eye injections?
NCT ID NCT04645212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the need for regular eye injections. The goal is to see if this one-time gene therapy can keep vision stable with less ongoing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
23 people
The number who actually took part.
- Started
-
Dec 2020
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
* Participants who received ADVM-022 at any dose in the OPTIC study * Up to 30 participants from all cohorts of OPTIC
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants who received a single dose of ADVM-022 at any dose in the OPTIC study * Willing and able to provide informed consent Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adverum Clinical Site
Bakersfield, California, 93309, United States
-
Adverum Clinical Site
Beverly Hills, California, 90211, United States
-
Adverum Clinical Site
Lakewood, Colorado, 80228, United States
-
Adverum Clinical Site
Deerfield Beach, Florida, 33064, United States
-
Adverum Clinical Site
Reno, Nevada, 89502, United States
-
Adverum Clinical Site
Philadelphia, Pennsylvania, 19107, United States
-
Adverum Clinical Site
Nashville, Tennessee, 37203, United States
-
Adverum Clinical Site
Bellaire, Texas, 77401, United States
-
Adverum Clinical Site
The Woodlands, Texas, 77384, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can fewer eye injections dry the retina in wet AMD?
- The 20-Minute squeeze: how eye injections push pressure up
- Could years of eye injections weigh down the upper eyelid?
- One shot in the eye: gene therapy aims to replace repeated injections for wet AMD
- New eye drug goes Head-to-Head with standard treatment for wet AMD
- New eye drug goes Head-to-Head with standard care for wet AMD